What changed today in Metabolic: 4 trial updates, 1 new study
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records6 sources1 min read
Peptide regulation
FDA and state regulatory developments affecting peptides, including which bulk drug substances may be used in compounding.
Building
- Editorial attention
- Building
- Tracked this week
- 7
- Sources this week
- 5
- Last activity
- 1 day ago
Signal strength reflects editorial attention across tracked sources — not medical certainty or strength of evidence.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
Peptide regulation at a glance
- About this topic
- FDA and state regulatory developments affecting peptides, including which bulk drug substances may be used in compounding.
- Current status
- No editor-reviewed status summary yet. The official records below update automatically.
- Last updated
- Primary sources
- Latest official record: New trial registered: Effects of a Gut-Active Peptide That Stimulates GLP-1 Release on Appetite and Satiety in Healthy Adults With Overweight (opens the source in a new tab) (ClinicalTrials.gov (U.S. National Library of Medicine), Nov 12, 2026)
- Key facts from tracked records
- Next verified date: Comments close: Compounding Animal Drugs From Bulk Drug Substances: Compounding Under CGMP in Federally-Registered Facilities; Draft Guidance for Industry; Availability; Agency Information… —
- 7 NPHLA briefings on this topic
What’s the latest on Peptide regulation?
7 totalWhat changed today in Regulatory: 2 safety alerts, 1 recall record
Every new official record on the Pharmacy, Compounding & Regulatory Intelligence desk since this morning, each linked to its primary source.
Automated from official records4 sources1 min read
What changed today in Regulatory: 1 new study
Every new official record on the Pharmacy, Compounding & Regulatory Intelligence desk since this morning, each linked to its primary source.
Automated from official records1 source1 min read
What changed today in Regulatory: 1 trial update, 1 recall record
Every new official record on the Pharmacy, Compounding & Regulatory Intelligence desk since this morning, each linked to its primary source.
Automated from official records4 sources1 min read
What changed today in Aesthetics & Longevity: 3 new studies, 1 trial update
Every new official record on the Aesthetics, Regenerative & Longevity Medicine desk since this morning, each linked to its primary source.
Automated from official records7 sources1 min read
What changed today in Metabolic: 4 new studies, 3 trial updates
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records9 sources1 min read
What changed today in Regulatory: 1 new study
Every new official record on the Pharmacy, Compounding & Regulatory Intelligence desk since this morning, each linked to its primary source.
Automated from official records2 sources1 min read
What do the official records show?
Primary sources and peer-reviewed research- New trial registered: Effects of a Gut-Active Peptide That Stimulates GLP-1 Release on Appetite and Satiety in Healthy Adults With Overweight (opens the source in a new tab)
Not applicable, Lembas. Conditions: Appetite and Hunger, Suppression; Satiety and Appetite; Weight Change; Gastrointestinal Symptoms; Body Composition. Interventions: Lembas Edge™; Placebo. Investigational: trial-stage therapies are not approved for the use studied.
- MedWatch Alert: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication (opens the source in a new tab)
FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication
- A Nature-Derived Peptide Promotes Satiety Hormone Response and Weight Loss In Vivo (opens the source in a new tab)
- New trial registered: H24LEAP2 (Investigating the Effects of 24 Hour LEAP2 Infusion in Individuals With Overweight and Obesity) (opens the source in a new tab)
Phase 1/Phase 2, University Hospital, Gentofte, Copenhagen. Conditions: Obesity & Overweight. Interventions: Liver-expressed antimicrobial peptide 2; Placebo. Investigational: trial-stage therapies are not approved for the use studied.
- Cutaneous Effects and Aesthetic Management of Glucagon-like Peptide-1 Receptor Agonists: A Narrative Review (opens the source in a new tab)
- The Future of Metabolic and Bariatric Surgery in the Glucagon-Like Peptide-1 Era: Has the Scalpel Become Obsolete? (opens the source in a new tab)
- Preventing Weight Regain After Glucagon-Like Peptide‑1 Therapy Discontinuation: A Pilot Randomized Controlled Trial (opens the source in a new tab)
- Glucagon-Like Peptide-1 Receptor Agonist-Associated Hepatotoxicity (opens the source in a new tab)
Industry coverage
Headlines link to the original publication- Hims & Hers Plans Launch of Peptide Treatments Following Federal Policy Shift (opens the source in a new tab)
- Earlier PRRT in Neuroendocrine Tumors: Treatment Selection and the Pharmacist’s Role (opens the source in a new tab)
- FDA Requires New Safety Warning on GLP-1 Medications for Rare Eye Condition (opens the source in a new tab)
- Earlier PRRT in Neuroendocrine Tumors Puts Pharmacists at the Center of Coordination (opens the source in a new tab)
- Argenx to buy peptide platform in potentially billion-dollar deal (opens the source in a new tab)